Scientific journal
Fundamental research
ISSN 1812-7339
"Перечень" ВАК
ИФ РИНЦ = 1,674

Personal portfolio

INFLIXIMAB IMPACT ON NEOANGIOGENESIS FACTORS AND ARTERIAL VASCULATURE RIGIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

Mesherina N.S. 1 Knyazeva L.A. 1 Goryainov I.I. 1
1 GBOU VPO «Kursk State Medical University, Ministry of Health and Social Development of Russia», Kursk
This article the results of research of serum levels of growth factors (VEGF-A, TGF-β1, FGF) and vasculature rigidity parameters in 38 patients with the seronegative (ACCP-negative) variant of rheumatoid arthritis against the background of treatment with infliximab. Increase of serum levels of VEGF-A, TGF-β1, FGF was determined in examined patients compared to the control group. Disturbances of arterial vasculature structural-functional properties were also found out – all examined patients with RA had a significant decrease of pulse wave transmission time (РТТ), increase of rigidity and augmentation indices, as well as of pulse wave transmission velocity. It was determined that arterial vasculature rigidity correlated with serum levels of growth factors in examined patients with RA. Treatment with infliximab is accompanied by significant decrease of serum levels of VEGF-A, TGF-β1, FGF and decrease of vasculature rigidity in patients with RA.
vasculature rigidity
infliximab
rheumatoid arthritis
growth factors
1. Ketlinskij, S.A. Citokiny. / S.A. Ketlinskij. S-Pb.: Foliant, 2008.550 р.
2. Marchenko Zh.A. Rol’ sosudistogo jendotelial’nogo faktora rosta v patogeneze revmatoidnogo artrita / Zh.A. Marchenko, Lukina G.V. // Nauchno-prakticheskaja revmatologija. 2005 no. 1. рр. 57-61.
3. Nasonov, E.L. Immunologicheskie markery ateroskleroza / E.L. Nasonov // Antifosfolipidnyj sindrom. M.: Litera, 2004. 298 p.
4. Nasonov, E.L. Problema aterotromboza v revmatologii / E.L. Nasonov // Vestn. RAMN. – 2003. no. 7. pp. 6–10.
5. Nedogoda S.V. Sosudistaja zhestkost’ i skorost’ rasprostranenija pul’sovoj volny: novye faktory riska serdechno-sosudistyh oslozhnenij i misheni dlja farmakoterapii / S.V. Nedogoda // Consilium Medicum: Bolezni serdca i sosudov. 2006. no. 4. pp. 25–29.
6. Novikov, A.A. Rol’ citokinov v patogeneze revmatoidnogo artrita / A.A. Novikov, E.N. Aleksandrova, M.A. Diatroptova // Nauchno-prakticheskaja revmatologija. 2010. no. 2. pp. 71–82.
7. Revmatologija: nacional’noe rukovodstvo / pod red. E.L. Nasonova, V.A. Nasonovoj. M.: GJeOTAR-Media, 2008. 852 p.
8. Juwuk, E.N. Jendotelial’naja disfunkcija pri zabolevanijah serdechno-sosudistoj sistemy i metody ee korrekcii / E.N. Juwuk, Ju.A. Vasjuk, A.B. Hadzegova, P.G. Filippov // Klinich. farmakologija i farmakoterapija. 2005. T. 1, no. 5. pp. 85–87.
9. Firestein G., Panayiand G., Wollheim F. Rheumatoid Arthritis. Oxford University Press, 2006;173–92.
10. Furst D.E., Keystone E.C., Fleischmann R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 //Ann. Rheum. Dis. 2010; 69 (Suppl II): i2-i29.
11. Infanger M., Kossmehl P., Shakibaei M., et al.Vascular endothelial growth factor inhibits programmed cell death of endothelial cells induced by clinorotation. J GravitPhysiol 2004; 11: pp. 199–200.
12. Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 2006;18:28997.
13. Maki-Petaja K.M., Hall F.C., Booth A.D. et al. Rheumatoid arthritis is associated with increased aortic pulse wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation, 2006;114:1185–92.

Рецензенты:

Никитин А.В., д.м.н., профессор, зав. кафедрой пропедевтики внутренних болезней ГБОУ ВПО «Воронежская государственная медицинская академия имени Н.Н. Бурденко» Министерства здравоохранения и социального развития Российской Федерации, г. Воронеж;

Вишневский В.И., д.м.н., профессор, зав. кафедрой внутренних болезней Медицинского института ФГБОУ ВПО «Орловский государственный университет», г. Орел.

Работа поступила в редакцию 09.10.2012.